CN1240147A - Kunyuan glg oral liquor - Google Patents
Kunyuan glg oral liquor Download PDFInfo
- Publication number
- CN1240147A CN1240147A CN 97118744 CN97118744A CN1240147A CN 1240147 A CN1240147 A CN 1240147A CN 97118744 CN97118744 CN 97118744 CN 97118744 A CN97118744 A CN 97118744A CN 1240147 A CN1240147 A CN 1240147A
- Authority
- CN
- China
- Prior art keywords
- parts
- days
- radix
- kunyuan
- glg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses an oral liquor for curing tumor. It is prepared from the Chinese-medicinal materials of cordyceps, ginseng, bupleurum root, peach kernel, arboreal fungus, coix seed and licorice as raw materials through pulverizing them, soaking them in 50% ethyl alcohol for 7 days, heating, refluxing, filtering, combining extracts, recovering ethyl alcohol, filtering, cold-storing the filtrate below 10 deg.C, standing for 3 days, filtering, taking out the supernatant fluid, regulating its total quantity to 1000 ml, uniformly stirring, filling and sterilizing to obtain the invented product. Said product can be used for curing more than 10 tumors such as mammary cancer, hyperplasia of mammary glands, fibroadenosis of breast, rectal cancer, oophoritic cyst, carcinoma of esophagus and leukemia, etc., and its effective rate is up to above 85%.
Description
The present invention relates to a kind of oral liquid for the treatment of tumor, is the oral liquid of feedstock production with the Chinese herbal medicine specifically, the invention still further relates to the preparation method of this oral liquid.
In the world today, 6,000,000 people that have an appointment every year suffer from oncosis, and 4,300,000 people that have an appointment die from this disease, therefore, it becomes a kind of serious harm and lists brainstorm project in, constantly develops various therapeutic method of traditional Chinese and western medicine, but real efficient ways is also rare, can't accomplish safe and effectively, remove patient's misery rapidly.Take operation, radiotherapy, chemotherapy as doctor trained in Western medicine, the patient will stand very big misery, and physiological function, the immunologic function of body all had major injury.And the medicine that the traditional Chinese medical science adopts such as Herba Catharanthi Rosei (newly) alkali, Folium et Ramulus Cephalotaxi, Herba Crotalariae sessiliflorae, colchicine and Fructus Bruceae emulsion, examine certain herbaceous plants with big flowers injection, TIANXIAN WAN capsule, Zhen Shi and set upright and fill agent, LIKANG CHONGJI etc. not only effect is slow, the course of treatment is long, and majority is toxic side effect all, brings new harm to the patient again.The BRM-102 herb liquid of the up-to-date development of Shanxi tumour hospital also can only alleviate infringement in radiotherapy, physical strength reinforcing, and treatment there is no effect to the tumor body.
The object of the present invention is to provide a kind of effect obviously, short treating period, the oral liquid of the treatment tumor that the treatment no pain has no side effect again.
Another object of the present invention provides the preparation method of the oral liquid of treatment tumor disease.
Solution of the present invention is based on motherland's medical science to the understanding of tumor invasion mechanism and treatment principle, with reference to the modern pharmacological research achievement, from motherland's medicine treasure-house, filters out the seven former medicines of flavor and makes.According to theory of Chinese medical science and experience prescription is discussed below: the generation of nodules of the breast, or by melancholy impairing the liver, depression of liver-QI, qi depression to blood stasis; Or by worry impairing spleen, transformation failure of spleen accumulates humidogene expectorant, causes disharmony of Chong and Conception Channels eventually, and newborn network blocks the poly-nucleation of knot, differs in size the nodules of the breast of meaning.Treatment is worked as with benefiting QI for activating blood circulation, and nuclear reason liver spleen, expectorant eliminating blood stasis and smoothing collaterals are method.We are monarch drug with Cordyceps and Radix Ginseng, but the two equal tonify deficiency profit and loss vital essence, the former still can " reduce phlegm " (" this strawman is new "), latter's " promoting blood circulation; broken hard long-pending " still all right (" not Lu "), recent studies can also be adjusted endocrine and immunologic function, is the non-defective unit of adjusting and runing yang.With Radix Bupleuri, Semen Persicae, Auricularia is minister, and wherein the Radix Bupleuri dispersing the stagnated live-QI to relieve the stagnation of QI is that depression of liver-QI is established, and the Semen Persicae promoting blood circulation to remove obstruction in the collateral is that stagnation of QI-blood is established, and the Auricularia replenishing QI to invigorate the spleen is that insufficiency of the spleen stagnation of phlegm is established, three medicines for principal drug assistance to reach the disappear effect of addiction of eliminating stagnation.With the Semen Coicis is assistant, invigorating spleen to remove dampness, and the source of its living expectorant of shutting out, Radix Glycyrrhizae both can help all product spleen invigorating of the monarch and his subjects benefit for making, and the property of medicine is in harmonious proportion, and the efficacy of a drug is single-minded.All medicine mutually 5, the outstanding dissipation among setting upright attacked and held concurrently and can consolidate in the heresy, the multitudinous healthy energy foot that makes, the stasis of blood is gone, the liver spleen and, the expectorant knot disappear and nodules of the breast from removing.Reliable with the disease curative effect of controlling nodules of the breast, safety non-toxic, to caused by hepatic stagnation qi stagnation, liver-kidney yin deficiency, the disharmony of Chong and Conception Channels type is imitated better.
The present invention forms (consumption is a weight portion) by following component:
10~30 parts of Cordyceps, 20~50 parts of Radix Ginsengs, 30~60 parts of Radix Bupleuri, 15~50 parts in Semen Persicae, 15~50 parts in Auricularia, 15~60 parts of Semen Coiciss, 5~40 parts in Radix Glycyrrhizae.
Above-mentioned each component is made preparation method of the present invention is: above-mentioned seven flavor medicine is ground into coarse powder, is dipped into weight and is in 1400~2000 parts 50% ethanol, soaked 7 days, reheat reflux, extract, twice each one hour, adds for the second time weight and is 700~800 parts 50% ethanol, filter, merge extractive liquid, reclaims ethanol, filter, filtrate cold preservation below 10 ℃ was placed 3 days, the leaching supernatant, adjust total amount to 1000ml, stir evenly, fill, sterilization is promptly.
Advantage of the present invention;
1, long-term toxicity test for animals shows safety non-toxic.
Prove through Colleges Of Traditional Chinese Medicine Of Shanxi: give rat, the female primordial oral liquid of 100 times of the dosage of being equivalent to be grown up, is checked its hemogram at totally 3 courses of treatment, and hepatic and renal function does becoming celestial and pathology section examination then, does not all find any untoward reaction.When showing this dosage of female primordial oral liquid, be safety non-toxic.
2, treatment female mammary gland proliferation disease
The II clinical trial phase is thought this new drug safety, effective, nontoxic.
By No.2 Affiliate Hospital, Shanxi Medical College, Taiyuan City central hospital, the II of Shanxi Province Tumor Hospital clinical trial phase.The result: 101 examples are organized in treatment, cure rate 39.6%, obvious effective rate 34.7%, total effective rate 95%; Matched group 33 examples, cure rate 9.1%, obvious effective rate 30.3%, 78.8%, two group of curative effect significant difference of effective percentage (P<0.05).Conclusion is thought this new drug safety, and is effectively, nontoxic.
3, treatment ovary simple cyst is through clinical observation, and effect is satisfied.
Since nineteen ninety-four 30 routine ovary simple cysts are treated through Shanxi Province Tumor Hospital, the result is as follows
(1) age: reckling 24 years old, the maximum 48 years old, average 36 years old.
(2) case source:
Be the outpatient service gynecologial examination and detect the female patient of examining to ovarian bursa increase or ovary simple cyst in conjunction with B ultrasonic, wherein 16 examples are for to be the compensatory capsule increase of ovary because of gynecologic surgery keeps one-sided adnexa, and 14 examples are found ovarian cyst because of first visit, are reluctant operator.
(3) lump size and position;
Lump is φ 6.0 * 6.5cm to the maximum, minimum φ 2.9 * 3.0cm, and the left side increases 17 examples, and the right side increases 13 examples.
(4) Therapeutic Method:
All the patient all singly obeys the Kunyuan glg oral liquor out-patient treatment, each 10ml, and day three times, be a course of treatment January, serve on for 3 courses of treatment, checks through the outpatient service doctor then, detects, contrasts, judges curative effect in conjunction with B ultrasonic.
(5) therapeutic outcome (standard)
The lump complete obiteration is recovery from illness, and it is produce effects that lump does not obviously dwindle the person, and it is obvious produce effects that lump continues obviously not dwindle the person, and lump does not have significant change person for invalid.
(6) result:
Total significant figure is 25 examples, accounts for 83%; Several 15 examples of wherein fully recovering account for 50%; Invalid number 5 examples account for 16.7%.
4, the special New Drug Certificate of sending out of Shanxi Province Department of Public Health
The special New Drug Certificate (Chinese medicine health-care medicine) of sending out of Shanxi Province Department of Public Health on March 1st, 1996, No. 01, numbering (96) Shanxi medicine authorized No..
Through how tame clinical trial, the present invention is to the treatment of ten kinds of tumors such as breast carcinoma, cyclomastopathy, mammary gland fibroma, rectal cancer, ovarian cyst, esophageal carcinoma, leukemia, the brain cancer, effective percentage reaches more than 85%, adversary's postoperative replaces chemotherapy, the cleaning focus, without any side effects, then take effect in the week soon.
Embodiment:
Press routine proportioning and take by weighing raw material:
Cordyceps 24g, Radix Ginseng 36g, Radix Bupleuri 48g, Semen Persicae 36g, Auricularia 36g, Semen Coicis 36g, Radix Glycyrrhizae 18g.
Preparation method:
With above-mentioned seven flavor medicine, be ground into coarse powder, be 6 times of seven flavor medicine with 50% ethanol consumption and soaked 7 days, reheat reflux, extract, twice each 1 hour, adds 50% ethanol of 3 times of amounts of seven flavor medicine consumption the second time, filter, merge extractive liquid, reclaims ethanol, filter, filtrate cold preservation below 10 ℃ was placed 3 days, the leaching supernatant, adjust total amount to 1000ml, stir evenly, fill, sterilization is promptly.
Claims (2)
1, a kind of Kunyuan glg oral liquor is made up of Cordyceps, Radix Ginseng, Radix Bupleuri, Semen Persicae, Auricularia, Semen Coicis, Radix Glycyrrhizae, is characterised in that it is to be made by the following weight proportion raw material; 10~30 parts of Cordyceps, 20~50 parts of Radix Ginsengs, 30~60 parts of Radix Bupleuri, 15~50 parts in Semen Persicae, 15~50 parts in Auricularia, 15~60 parts of Semen Coiciss, 5~40 parts in Radix Glycyrrhizae.
2, the preparation method of Kunyuan glg oral liquor according to claim 1, it is characterized in that the seven flavor medicine described in the claim 1 is ground into coarse powder, be dipped into weight and be in 1400~2000 parts 50% ethanol, soaked 7 days, reheat reflux, extract, twice each one hour, adds for the second time weight and is 700~800 parts 50% ethanol, filter, merge extractive liquid, reclaims ethanol, filters, filtrate cold preservation below 10 ℃ was placed 3 days, the leaching supernatant is adjusted total amount to 1000ml, stirs evenly, fill, sterilization promptly.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN97118744A CN1094054C (en) | 1997-09-29 | 1997-09-29 | Kunyuan glg oral liquor |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN97118744A CN1094054C (en) | 1997-09-29 | 1997-09-29 | Kunyuan glg oral liquor |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1240147A true CN1240147A (en) | 2000-01-05 |
CN1094054C CN1094054C (en) | 2002-11-13 |
Family
ID=5174936
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN97118744A Expired - Fee Related CN1094054C (en) | 1997-09-29 | 1997-09-29 | Kunyuan glg oral liquor |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1094054C (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002080951A1 (en) * | 2001-04-06 | 2002-10-17 | Synergistix Biotech, Inc. | Herbal extracts for the treatment of cancer |
US20120003342A1 (en) * | 2010-06-30 | 2012-01-05 | Industrial Technology Research Institute | Pharmaceutical composition for treating or releiving inflammatory bowel disease |
US20160175375A1 (en) * | 2014-12-17 | 2016-06-23 | Yuan-Jen Chang | Preparation of orally administrable pharmaceutical composition containing traditional chinese medicine for hematologic diseases |
CN105998908A (en) * | 2016-07-11 | 2016-10-12 | 李宗贤 | Chinese herba preparation for treating tumors and resisting toxic and side effects of chemotherapy and preparation method thereof |
-
1997
- 1997-09-29 CN CN97118744A patent/CN1094054C/en not_active Expired - Fee Related
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002080951A1 (en) * | 2001-04-06 | 2002-10-17 | Synergistix Biotech, Inc. | Herbal extracts for the treatment of cancer |
US20120003342A1 (en) * | 2010-06-30 | 2012-01-05 | Industrial Technology Research Institute | Pharmaceutical composition for treating or releiving inflammatory bowel disease |
US9060989B2 (en) | 2010-06-30 | 2015-06-23 | Industrial Technology Research Institute | Method for treating or relieving inflammatory bowel disease |
US20160175375A1 (en) * | 2014-12-17 | 2016-06-23 | Yuan-Jen Chang | Preparation of orally administrable pharmaceutical composition containing traditional chinese medicine for hematologic diseases |
CN105998908A (en) * | 2016-07-11 | 2016-10-12 | 李宗贤 | Chinese herba preparation for treating tumors and resisting toxic and side effects of chemotherapy and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
CN1094054C (en) | 2002-11-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100396326C (en) | Mastoproliferation treating medicine and its preparing method | |
CN101204559A (en) | Medicaments composite for coronary heart disease, angina and epigastralgia and preparation method thereof | |
CN1094054C (en) | Kunyuan glg oral liquor | |
CN1060391C (en) | Traditional Chinese medicine for treating gynecological tumour | |
CN1334119A (en) | Litholysizing bear gall powder | |
CN1141110C (en) | Preparation of cancer treating medicine capsule | |
CN109248305A (en) | A kind of Chinese medicine composition and preparation method thereof for treating liver fibrosis | |
CN1879783A (en) | A medicine for treating diabetes | |
CN1223886A (en) | Pathogenic factor eliminating and healthy energy supporting anticancer medicine | |
CN102755515A (en) | Traditional Chinese medicine decoction for treating hyperplasia of mammary glands | |
CN1160099C (en) | Anti-cancer recovery capsule and preparation process thereof | |
CN1215875C (en) | Peroral Chinese medicine powder for treating bone fracture and its preparing process | |
CN1116050C (en) | Medicine bolus for dredging meridian passage, nourishing blood and removing toxic material | |
CN101549057A (en) | Chinese medicine composition for curing hyperlipemia, cerebral arteriosclerosis and ischemic apoplexy and method of preparing the same | |
CN1270768C (en) | Medicine for treating cold disease | |
CN1163252C (en) | Tianjian capsule and its preparing process | |
CN1083269C (en) | Chinese herbal medicine for treating hysteromyoma and breast fibrosarcoma and its prepn. method | |
CN101147796B (en) | Application of 'xiaozhengyin' in preparing medicine for treating proliferation of mammary gland | |
CN1772248A (en) | Gastric ulcer treating medicine | |
CN101028401A (en) | Oral Chinese medicine for treating difficult menstruation | |
CN102225132A (en) | Traditional Chinese medicine compound for treating hyperlipidaemia, cerebral arteriosclerosis and ischemic stroke and preparation method thereof | |
CN101249183A (en) | Capsules for curing hypertension and condensed blood lipid | |
CN1596943A (en) | Leech capsule | |
CN1057919C (en) | Medicinal preparation for treatment of tumour | |
CN1836705A (en) | Medicine for treating amblyopia and its preparing method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |